SCHEMBL7693220

SCHEMBL7693220

CCN(CC)CCCCNc1ncc2nc(-c3ccccc3)c(O)nc2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CACNA2D1 P54289 1/20 0.46
▸ FGFR1 P11362 9/20 0.46
▸ KDR P35968 3/20 0.46
▸ EGFR P00533 3/20 0.45
▸ FGFR2 P21802 3/20 0.42
▸ FGFR4 P22455 3/20 0.42
▸ FGFR3 P22607 3/20 0.42
▸ SRC P12931 2/20 0.42
▸ POLB P06746 1/20 0.42
▸ PRKD3 O94806 1/20 0.41
▸ PRKCG P05129 1/20 0.41
▸ PRKCB P05771 1/20 0.41
▸ PRKCA P17252 1/20 0.41
▸ PRKCH P24723 1/20 0.41
▸ PRKCI P41743 1/20 0.41
▸ PRKCE Q02156 1/20 0.41
▸ PRKCQ Q04759 1/20 0.41
▸ PRKCZ Q05513 1/20 0.41
▸ PRKCD Q05655 1/20 0.41
▸ PRKD1 Q15139 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7696148 0.80 CACNA2D1 (0.46) CACNA2D1FGFR1KDREGFRFGFR2
SCHEMBL7696545 0.77 TSHR (0.45) CACNA2D1FGFR1KDREGFRFGFR2
SCHEMBL7695093 0.72 CYP1A2 (0.46) SRCTP53USP2ALDH1A1CYP1A2
SCHEMBL2326504 0.69 TP53 (0.52) CACNA2D1FGFR1KDRPOLBTP53
SCHEMBL10371119 0.68 ADORA1 (0.50) ADORA1ALDH1A1GLAGAAMERTK
SCHEMBL10367538 0.68 ADORA1 (0.50) ADORA1ALDH1A1GLAGAAMERTK
SCHEMBL8288058 0.64 CACNA2D1 (1.00) CACNA2D1POLBGAA
SCHEMBL4259413 0.64 MERTK (0.55) FGFR1EGFRFGFR2FGFR4FGFR3
SCHEMBL12120391 0.64 CACNA2D1 (0.68) CACNA2D1POLBALDH1A1GAA
SCHEMBL14569051 0.64 FGFR1 (0.57) FGFR1KDREGFRFGFR2FGFR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2002076985-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES SMITHKLINE BEECHAM CORPORATION (US) 2002-10-03 — — WO disclosed
Send feedback